Background: Multiple group B Streptococcus (GBS) isolates with reduced penicillin susceptibility (PRGBS) were recovered from several patients, hence a probable nosocomial transmission of PRGBS in a hospital setting was suspected.
Introduction
Group B Streptococcus (GBS) is one of the most important causes of serious neonatal infections. In particular, for early onset neonatal diseases, rectal or vaginal GBS colonization found in about 25% of pregnant women is the primary risk factor. GBS also causes invasive infections in adults, including pregnant women, elderly individuals and immunocompromised patients. Penicillin is the first-line antibiotic for treatment of GBS infection, as well as for intrapartum antibiotic prophylaxis to prevent early onset infection, because resistance to this agent has not been reported so far among GBS clinical isolates. However, in 2008 we reported GBS clinical isolates with reduced penicillin susceptibility (PRGBS), 1, 2 in which an increase was noted in the MICs of b-lactam antibiotics including penicillin (MICs of 0.25-1 mg/L). Since no typical phenotypic changes are observed between GBS and PRGBS, it is very difficult to distinguish them in routine microbiology tests. However, elevation of ceftizoxime and ceftibuten MICs would be a good marker for screening for PRGBS, 1, 3 although these agents are not included in the list of drugs for antimicrobial susceptibility testing. Amino acid substitutions V405A and Q557E in penicillin-binding protein (PBP) 2X, which are shared by most PRGBS strains, have been demonstrated as a major mechanism involved in reduction of GBS penicillin susceptibility. 1 Besides these two key substitutions that have been identified in PBP 2X, multiple amino acid substitutions were also found in PBPs 2X, 2B and 1A among PRGBS strains depending on their penicillin MIC levels. However, it has also been noted that one of those PRGBS strains had no such key substitution in PBP 2X. 1 After our aforementioned study, GBS strains isolated in the USA, showing elevated MICs, but which were still susceptible to b-lactam antibiotics, shared amino acid substitution Q557E in PBP 2X, 4 whereas GBS strains with penicillin MICs of 0.25 or 0.5 mg/L from two Canadian studies had amino acid substitutions in several PBPs, but no key substitutions-V405A or Q557E-were found in PBP 2X. 5, 6 Interestingly, the amino acid substitutions identified in PBPs of these Canadian PRGBS strains have not been found so far among the strains tested in our studies. Thus characterization of molecular mechanisms underlying the reduced penicillin susceptibility profile in PRGBS is still in progress.
Clindamycin or erythromycin is traditionally used for GBS intrapartum prophylaxis for penicillin-allergic women at high risk of anaphylaxis. However, increasing resistance of GBS to clindamycin or erythromycin has been reported worldwide. In the USA, the rates of resistance among invasive GBS isolates were 13% -15% for clindamycin and 26% -32% for erythromycin. 7, 8 The Japan Nosocomial Infections Surveillance (JANIS) of the Ministry of Health, Labour and Welfare showed that the prevalence of resistance was 22% and 28% for clindamycin and erythromycin, respectively, among GBS from various clinical sources in 2010. 9 In GBS isolates, macrolide resistance has been mediated mainly by two classes of resistance genes: the erm genes, including erm(B), erm(TR)/erm(A) and erm(C), which mediate ribosomal methylation; and the mef genes, such as mef(A) and mef(E), which are involved with efflux of macrolides as they encode membrane-associated transporters. The erm genes are associated with the macrolide-lincosamide-streptogramin B resistance phenotype, which usually show cross-resistance to clindamycin, while mef genes are the resistance determinants specific for 14-and 15-membered macrolides.
Fluoroquinolone resistance in GBS has recently emerged in several countries including Japan. 10 -14 Mutations in the quinolone resistance-determining regions (QRDRs) of the genes encoding topoisomerase IV ParC and DNA gyrase GyrA have mainly been associated with fluoroquinolone resistance of this organism. 10, 11, 13, 15 The presence of GyrA-ParC-ParE triple mutations has recently been reported in Taiwan isolates.
14 High rates of tetracycline resistance have also been noted among GBS isolates with the most common resistance determinant, tet(M), which encodes the ribosomal protection protein. 16, 17 Our phylogenetic comparative analyses have shown genetic diversity of pbp genes among PRGBS strains, while those genes of the penicillin-susceptible strains were highly conserved, irrespective of their isolation dates. 2 Furthermore, a phylogenic tree showed three distinct genetic lineages of PRGBS strains, implying that those lineages have been independently emerging through the accumulation of different genetic mutations in their pbp genes during evolution. PRGBS has been found to be capable of surviving persistently at the site of infection for .3 weeks. 18 In the present study we investigated the molecular basis of resistance determinants and the clonal relationship of 10 PRGBS isolates showing multidrug resistance to macrolides, lincosamides, fluoroquinolones and tetracyclines detected from eight patients during a 5 month period to characterize the genetic background of the isolates.
Materials and methods

Bacterial strains
Ten GBS clinical strains isolated from eight patients admitted to a general hospital located in Tokyo, Japan, during March -August 2007 were analysed. These strains included two strains, strain numbers 2-1 and 2-2, isolated from different specimens obtained at approximately the same time from one patient and two strains, strain numbers 4-1 and 4-2, isolated at 2 month intervals from another patient. The source of strains and the clinical backgrounds of the patients are shown in Table 1 .
GBS strains were grown overnight in Todd-Hewitt broth (BD Diagnostics) and then stored in glycerol at 2808C until use.
Serotyping was performed using antisera (Denka Seiken, Tokyo, Japan) to the type-specific capsular polysaccharides Ia, Ib, II, III, IV, V, VI and VIII.
Antimicrobial susceptibility testing
MICs were determined using a broth microdilution method with a MicroScan MICroFAST panel type 5J system (Dade Behring Inc., Tokyo, Japan) by following the guidelines recommended by the CLSI. 19 For susceptibility categories we referred to the CLSI criteria. 20 Additionally, MICs of penicillin and ceftizoxime were determined by Etest according to the manufacturer's instructions (AB Biodisk, Solna, Sweden).
MIC determinations were repeated independently three times for each strain to ensure the reproducibility of the MICs by using quality control strain Streptococcus pneumoniae ATCC 49619.
Susceptibility testing with a ceftibuten disc was also performed by Kirby -Bauer's disc-diffusion method. 
Analysis of pbp gene sequences
PCR amplification and sequencing analysis of each pbp gene were performed as previously described, with minor modifications. 2 Briefly, the full-length coding regions of pbp1a, pbp2b and pbp2x genes were amplified from genomic DNA extract using the primer pairs f1 and r1, as listed in Table 2 . PCRs were carried out using PrimeSTAR HS DNA polymerase (Takara Shuzo Co., Kyoto, Japan) with reaction conditions of 30 cycles of 988C for 10 s, 558C for 5 s and 728C for 2.5 min.
Sequencing analyses of both strands of purified PCR products were performed using several internal forward and reverse sequencing primers (Table 2) , a BigDye Terminator (version 3.1) cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI 3730x/DNA analyser (Applied Biosystems).
The nucleotide sequences obtained were assembled into contigs with BioEdit (version 5.0.9) software (http://www.mbio.ncsu.edu/BioEdit/ bioedit.html), then aligned with ClustalW software. 21 Streptococcus agalactiae strains 2603 V/R (ATCC BAA-611; GenBank accession number NC004116) and NEM316 (ATCC 12403; GenBank accession number NC004368) were used as reference strains for comparative analysis.
Analysis of macrolide and fluoroquinolone resistance
PCR detection of erm(B), erm(TR) and mef(A/E), conferring resistance to macrolides or lincosamides, was performed with specific primers shown in Table 2 as described previously. 22, 23 For three representative strains, the PCR products were subjected to sequence analyses to confirm the identity of amplification products.
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PCR amplification and DNA sequencing of the gyrA, gyrB and parC genes, which include the QRDRs responsible for the fluoroquinolone resistance phenotype, were performed using primers specifically designed from known DNA sequences of strain 2603 V/R as shown in Table 2 . PCR and sequence analysis were carried out as described above except for an extension time of 1 min.
PFGE
PFGE of SmaI (Takara)-digested chromosomal DNAs was performed as previously described by Nagano et al. 2 Lambda DNA ladder (48.5 kb-1 Mb; Takara) was used as a molecular size marker. PFGE results were interpreted according to the Tenover's criteria. 24 
Multilocus sequence typing (MLST)
MLST was performed as described previously. 25 Amplification of seven housekeeping genes-adhP, pheS, atr, glnA, sdhA, glcK and tkt-by PCR was carried out using amplification primers and PrimeSTAR HS DNA polymerase (Takara) with reaction conditions of 1 cycle of 988C for 1 min, followed by 30 cycles of 988C for 10 s, 558C for 15 s and 728C for 1 min, and finally 1 cycle of 728C for 7 min. PCR products were purified and sequenced using sequencing primers. Allelic profile assignment and sequence type (ST) determinations were made using the GBS MLST databases (http://pubmlst.org/sagalactiae). eBURST analysis was performed to define clonal complexes (CCs) within the isolates by using the eBURST program (http://eburst.mlst.net/v3/enter_data/single/).
Results
Origin of GBS strains
GBS strains were obtained from eight inpatients (five females and three males), aged 52-86 years (mean age 77.6+11 years) ( Table 1) . Four patients were admitted to neurosurgery in ward A and the remaining four patients were admitted to internal medicine, among whom three were in ward B and one was in ward C. b-Lactams had been administered in all patients except one, whose history of prior therapy was unknown, and ciprofloxacin had been prescribed for three patients within 3 months of isolation of GBS. All GBS clinical strains showed no growth inhibitory zone around the ceftibuten disc, suggesting PRGBS. 3 Of those 10 isolates, 5 (strains 1, 2-2, 3, 4-1 and 7) were recovered from pharyngeal swab samples, 4 (strains 4-2, 5, 6 and 8) were from transtracheal aspirate samples and 1 (strain 2-1) was from pus obtained from the gastrostomy site. All strains were serotyped as type VI.
MICs
The MICs of several antimicrobial agents for S. pneumoniae ATCC 49619 were all within the quality control ranges defined by the CLSI, 20 and reproducible MIC results were obtained for GBS strains tested against all antimicrobials ( Table 1) .
The broth microdilution method showed that the MICs of penicillin and ampicillin were 0.25 mg/L and 0.5 mg/L, respectively, for eight strains, against 0.12 mg/L and 0.25 mg/L, respectively, for strains 4-1 and 8. However, reproducible results of a penicillin MIC of 0.25 mg/L were obtained by the Etest for these two strains. Thus all 10 strains were confirmed to be PRGBS. The MICs of cefotaxime, ceftriaxone and meropenem for PRGBS strains were all still within the susceptible range (≤0.5 mg/L), as shown in Table 1 , but were higher than those for penicillin-susceptible strains possessing no amino acid substitutions in PBPs 2X, 2B or 1A. 2 The MICs of erythromycin, clarithromycin and clindamycin were .1 mg/L for all isolates tested, which fell into the resistant category. The 10 strains were resistant to levofloxacin, including MICs .8 mg/L for eight strains and 8 mg/L for strains 3 and 6. All strains were resistant to tetracycline (MIC .4 mg/L), but susceptible to vancomycin. b-Lactamase activity was not detected in any of the PRGBS isolates.
Nucleotide sequences and amino acid substitutions in PBPs 2X, 2B and 1A DNA sequencing of the pbp genes revealed that pbp2x, pbp2b and pbp1a genes of 10 PRGBS strains were identical. Those strains shared 10 nucleotide mutations, including five nonsynonymous substitutions in pbp2x genes when compared with the corresponding genes of strains 2603 V/R and NEM316. The PBP 2X amino acid substitutions included a key substitution, V405A, and four additional substitutions-F395L, R433H, H438Y and G648A-that had been unique to PRGBS in our previous studies. 1, 2 In PBP 2B, one amino acid substitution, T567I, which had been unique to PRGBS, was found. No amino acid substitutions were observed in PBP 1A (Table 3) .
Macrolide and fluoroquinolone resistance determinants
Amplification of DNA from 10 PRGBS strains yielded PCR products of the expected sizes (442 bp) with erm(B)-specific primers. Sequence analyses of the PCR products from three representative strains-1, 3 and 8-selected on the basis of PFGE types revealed that the sequences of those amplified products were identical to the erm(B) gene sequence in GenBank accession number EF422361. All strains were negative for the erm(TR) and mef(A/E) genes. Table 4 summarizes the QRDR amino acid substitutions in GyrA, GyrB and ParC of the PRGBS strains. Eight strains-1, 2-1, 2-2, 4-1, 4-2, 5, 7 and 8-for which levofloxacin MICs were .8 mg/L had an E476K substitution in GyrB in addition to S81L in GyrA and S79Y substitutions in ParC. The remaining strains-3 and 6-for which levofloxacin MICs were 8 mg/L, also had E476K in GyrB and S79Y in ParC, but had no substitutions in GyrA. Figure 1 shows the PFGE results of SmaI-digested chromosomal DNAs from 10 PRGBS strains, representing three different PFGE patterns. The predominant PFGE type I included seven strains-1, 2-1, 2-2, 4-1, 4-2, 5 and 7-all of which were derived from ward A, except strain 7 from ward B. PFGE type II included strains 3 and 6 derived from ward B, and type III included strain 8 from ward C. PFGE types II and III differed from PFGE type I by four and three bands, respectively, and those three types were therefore considered to have a similar genetic background.
PFGE and MLST analyses
PFGE type I strains had the QRDR amino acid substitutions in GyrA, GyrB and ParC, but PFGE type II strains had those in only GyrB and ParC (Table 4) .
All 10 PRGBS with the allelic profile 1, 1, 2, 1, 1, 2 and 3, in the order adhP, pheS, atr, glnA, sdhA, glcK and tkt, were assigned to ST458, which is a single-locus variant of ST1 within CC1.
Discussion
This study describes a probable nosocomial spread of PRGBS caused by genetically very similar PRGBS isolates that acquired multidrug resistance to macrolides, lincosamides, fluoroquinolones and tetracyclines, as well as several oral cephalosporins such as ceftizoxime. 1, 3 Among 10 PRGBS isolates derived from eight patients, a close genetic relationship was strongly suggested by PFGE analysis. Four patients in ward A and one patient in ward B had strains with the predominant PFGE type (pulsotype) I, and these strains were isolated in the same period, indicating probable bacterial transmission between these wards. Transmission of PRGBS strains was also noted in ward B, where two patients were found to share the same strains with pulsotype II. A strain with pulsotype III was isolated from a patient in ward C on the day of her admission, so it was suggested that the strain might have been introduced into the hospital from the community or other medical settings. The isolation of PRGBS strains with pulsotype II was preceded by those with pulsotype I, which, initially, might lead one to assume that pulsotype II strains are derivatives of pulsotype I strains. However, pulsotype I strains had the QRDR amino acid substitutions in GyrA, GyrB and ParC, whereas pulsotype II strains had those only in GyrB and ParC, which contradicted our speculation. Thus it may well be that genetically related strains of pulsotypes I and II spread separately on a ward or between two wards. PRGBS strains 4-1 and 4-2 sharing pulsotype I were detected from a patient over a 2 month interval, suggesting those strains might colonize persistently, as has been observed previously. 18 In eight PRGBS strains of pulsotypes I and III with levofloxacin MICs .8 mg/L, E476K in GyrB was newly detected, together with two substitutions S81L in GyrA and S79Y in ParC, which have been found to be involved with high-level fluoroquinolone resistance. The remaining two strains of pulsotype II for which levofloxacin MICs were 8 mg/L also had E476K in GyrB and S79Y in ParC, but had no substitutions in GyrA. To the best of our knowledge, although amino acid substitutions in GyrB have not been reported in GBS, E476K, which corresponds to the E474K substitution in S. pneumoniae, may possibly contribute to fluoroquinolone resistance, as has been suggested for S. pneumoniae.
26
Clindamycin can be used as intrapartum GBS prophylaxis for penicillin-allergic GBS carriers, as has been endorsed by the CDC. 27 All PRGBS strains in this study showing consistent resistance to macrolides and lincosamides harboured erm(B) genes that confer high resistance levels to these agents. This finding enhances the need for monitoring of GBS strains multiresistant to macrolides and lincosamides. Those strains were also resistant to tetracycline, and erythromycin resistance genes have sometimes been found on the mobile genetic elements encoding tetracycline resistance genes. 28, 29 The nucleotide sequences of the coding regions of pbp2x, pbp2b and pbp1a genes were completely identical in all 10 PRGBS, although the strains were divided into three genetically related PFGE types. Five amino acid substitutions, including a key substitution (V405A) identified in PBP 2X, have been found to be unique to PRGBS. 1, 2 In PBP 2B, one amino acid substitution that is also unique to PRGBS was found. It is of interest that those sequences found in pbp2x, pbp2b and pbp1a genes were 100% identical to the corresponding sequences of the PRGBS strain R5, which has been reported previously. 2 Moreover, the deduced amino acid sequences of PBPs 2X, 2B and 1A were completely identical to the corresponding sequences of the previously described PRGBS strains R1, R2, R5 and R6, which has one additional substitution in PBP 2X. Ten PRGBS strains characterized in the present study and PRGBS strains R1, R2, R5 and R6, which have been found to form one of the three distinct lineages of the pbp genes in our previous study, 2 were all serotype VI and had closely related PFGE profiles. MLST analysis Nagano et al.
showed that all 10 PRGBS were ST458, which is a single-locus variant of ST1 belonging to CC1. Interestingly, PRGBS strains R1, R2, R5 and R6 were serotype VI and were also assigned to ST458, which has been reported to be the predominant ST among PRGBS in Japan. 30 Thus the spread of a clonal serotype VI PRGBS population of ST458 has occurred in geographically separate areas, while acquiring resistance to macrolides, lincosamides and fluoroquinolones over time. ST458, which has been assigned as a new ST to our PRGBS strains, has not been detected among PRGBS strains from other countries. 4, 6 The serotype VI PRGBS with ST458 may well be defined as the Japan clone.
EUCAST (http://www.eucast.org/clinical_breakpoints/) has established a clinical breakpoint for penicillin and Streptococcus groups A, B, C and G, including the resistance criteria of penicillin MIC .0.25 mg/L. However, EUCAST notes that the strains with MIC values above the epidemiological cut-off value (0.25 mg/L) are very rare or not yet reported, and they should be reported as 'resistant' until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint. According to CLSI M100-S21, 20 only susceptible interpretive criteria are available for penicillin and b-haemolytic streptococci, with several comments, e.g. non-susceptible isolates with penicillin MICs .0.12 mg/L and ampicillin MICs .0.25 mg/L are extremely rare in b-haemolytic streptococci and have not been reported for group A Streptococcus. CLSI also states that susceptibility testing of penicillins and other b-lactams for the treatment of b-haemolytic streptococcal infections need not be performed routinely. However, in Canada, the development of penicillin non-susceptibility in GBS has been described in vivo in adult patients by acquiring amino acid substitutions in PBPs during prolonged administration of penicillin V. 5, 6 These findings underscore the necessity of routinely monitoring the levels of penicillin MICs, especially when penicillins or cephalosporins are prescribed to a patient over a long period. Moreover, in the present study we have demonstrated probable horizontal transmission of PRGBS strains among patients, leading to their nosocomial spread for at least 5 months. The clinical significance of PRGBS isolates in antimicrobial chemotherapy and also in intrapartum prophylaxis remains unclear. Thus investigation and discussion should be encouraged to predict the therapeutic effect of penicillin therapy, especially for more invasive GBS infections such as meningitis due to PRGBS.
Our findings extend the knowledge about PRGBS with regard to more serious therapeutic and prophylactic problems posed by the possible future prevalence of multidrug-resistant genotypes of PRGBS, together with their ability to spread and survive in hospital environments. The emergence of multidrug-resistant PRGBS is a concern regarding future global spread, as we have experienced with multidrug-resistant S. pneumoniae, 31, 32 and again emphasizes the need for careful epidemiological monitoring of GBS strains to assess the current prevalence status of PRGBS as well as their multidrug-resistant genotypes.
